CN Patent

CN104220064B — 一种含辛弗林和托吡酯的联合产品

Assigned to Institute of Pharmacology and Toxicology of AMMS · Expires 2017-10-10 · 9y expired

What this patent protects

本发明提供了一种含辛弗林和托吡酯的联合产品，其中辛弗林或其盐以速释的制剂形式给药，优选速释微丸，日服药剂量为2mg到25mg，优选5mg到20mg；托吡酯以缓释或控释的制剂形式给药，优选缓释微丸，日服药剂量为20mg到100mg，优选23mg到92mg。该组合物用于治疗肥胖症以及与肥胖症相关的其他疾病。

USPTO Abstract

本发明提供了一种含辛弗林和托吡酯的联合产品，其中辛弗林或其盐以速释的制剂形式给药，优选速释微丸，日服药剂量为2mg到25mg，优选5mg到20mg；托吡酯以缓释或控释的制剂形式给药，优选缓释微丸，日服药剂量为20mg到100mg，优选23mg到92mg。该组合物用于治疗肥胖症以及与肥胖症相关的其他疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN104220064B
Jurisdiction
CN
Classification
—
Expires
2017-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Institute of Pharmacology and Toxicology of AMMS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.